Literature DB >> 31540901

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies.

Angela C Weyand1, Veronica H Flood2,3,4, Jordan A Shavit1, Steven W Pipe1,5.   

Abstract

Entities:  

Year:  2019        PMID： 31540901      PMCID： PMC6759735          DOI： 10.1182/bloodadvances.2019000656

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  6 in total

Review 1.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

2.  Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay.

Authors:  Connie H Miller
Journal:  Haemophilia       Date:  2021-06-05       Impact factor: 4.263

Review 3.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

Review 4.  Prophylactic management of patients with von Willebrand disease.

Authors:  Massimo Franchini; Omid Seidizadeh; Pier Mannuccio Mannucci
Journal:  Ther Adv Hematol       Date:  2021-12-22

Review 5.  Non-factor therapies for bleeding disorders: A primer for the general haematologist.

Authors:  Dawn Swan; Johnny Mahlangu; Jecko Thachil
Journal:  EJHaem       Date:  2022-04-28

6.  Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor.

Authors:  Andrew Yee; Manhong Dai; Stacy E Croteau; Jordan A Shavit; Steven W Pipe; David Siemieniak; Fan Meng; David Ginsburg
Journal:  J Thromb Haemost       Date:  2021-07-28       Impact factor: 16.036
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.